Journal article · Research (general)← The news desk

✦ The Dispatch

Psychopharmacological Mechanisms of Antidepressant Withdrawal: Insights From Venlafaxine

A dispatch from PubMed — filed

Antidepressant discontinuation syndrome (ADS) is widely reported yet often minimized by terminology that obscures its status as a withdrawal phenomenon. Roughly one-third of patients using a monotherapy antidepressant develop withdrawal symptoms after discontinuation, with higher rates among patients taking venlafaxine (VEN) and those treated long-term....

Continue reading at PubMed

✦ The floor

Discussion

Signed responses from readers of the wire.

✦ Clinical Takeaway ✦

No actionable change — this review concerns antidepressant withdrawal pharmacology and has minimal relevance to hearing healthcare.

✦ Why It Matters ✦

While antidepressants are occasionally implicated in ototoxicity (medication-related hearing damage), this review does not address hearing outcomes and carries essentially no clinical significance for audiologists.

✦ Key Points ✦
  1. 01Review published in Human Psychopharmacology examines venlafaxine withdrawal mechanisms.
  2. 02Authors argue antidepressant discontinuation syndrome is a true withdrawal phenomenon, not relapse.
  3. 03No audiology-specific findings, outcomes, or patient populations are discussed.
  4. 04Minimal hearing-health relevance identified by indexing source.
✦ Research metadata ✦
PMID
42663396
DOI
10.1002/hup.70061.
Journal
Human Psychopharmacology: Clinical and Experimental
Publication type
review
Evidence level
5
Population
Not applicable — narrative review of pharmacological literature on venlafaxine withdrawal
Intervention
Venlafaxine discontinuation / antidepressant withdrawal

Primary outcomes

Psychopharmacological mechanisms underlying antidepressant discontinuation syndrome

✦ Related stories ✦